William Richard White Sells 7,136 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 7,136 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

William Richard White also recently made the following trade(s):

• On Friday, November 1st, William Richard White sold 201 shares of Disc Medicine stock. The shares were sold at an average price of $46.37, for a total value of $9,320.37.
• On Tuesday, October 1st, William Richard White sold 201 shares of Disc Medicine stock. The shares were sold at an average price of $51.31, for a total value of $10,313.31.

Disc Medicine Trading Down 2.3 %

NASDAQ:IRON opened at $63.33 on Friday. The firm has a 50-day moving average price of $49.66 and a two-hundred day moving average price of $43.48. Disc Medicine, Inc. has a twelve month low of $25.60 and a twelve month high of $77.60. The company has a market capitalization of $1.88 billion, a P/E ratio of -17.26 and a beta of 0.60.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.08. On average, equities research analysts predict that Disc Medicine, Inc. will post -4.09 earnings per share for the current year.

Institutional Trading of Disc Medicine

Institutional investors and hedge funds have recently made changes to their positions in the company. Quest Partners LLC purchased a new stake in shares of Disc Medicine in the third quarter worth about $131,000. China Universal Asset Management Co. Ltd. grew its position in shares of Disc Medicine by 96.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,717 shares of the company’s stock worth $281,000 after buying an additional 2,813 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after acquiring an additional 337 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Disc Medicine by 19.5% in the third quarter. SG Americas Securities LLC now owns 4,864 shares of the company’s stock worth $239,000 after purchasing an additional 793 shares during the period. Finally, Teachers Retirement System of The State of Kentucky bought a new position in shares of Disc Medicine in the 2nd quarter worth about $636,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research note on Tuesday, October 15th. Scotiabank increased their target price on shares of Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a research note on Tuesday. Wells Fargo & Company assumed coverage on shares of Disc Medicine in a report on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price objective on the stock. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their price target for the company from $66.00 to $110.00 in a research note on Monday. Finally, Wedbush reiterated an “outperform” rating and set a $75.00 price objective (up from $60.00) on shares of Disc Medicine in a research note on Monday. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $80.20.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.